Executive Summary
This procedural order addressed a request for protection of confidential information filed by several TCL entities in an infringement action against NEC Corporation. The UPC Court confirmed the confidentiality status of sensitive documents related to FRAND negotiations and counterclaims. The ruling sets out strict rules governing who can access this proprietary data, ensuring that it is only used within the scope of the litigation. This decision reinforces the procedural mechanisms available under the UPCA for protecting trade secrets during complex patent disputes.
What the Court Held — Ratio Decidendi
The Court confirmed that the formal requirements for requesting confidentiality under Rule 262A RoP were met. It ruled that the specified information related to negotiations and FRAND Counterclaim must be treated as confidential, subject to strict limitations on use and disclosure.
Practitioner Note
This decision granted relief to the petitioner. If you are facing a similar patent dispute before Munich (DE) Local Division, this precedent supports interim or final relief where the facts are comparable. The ratio regarding the applied tests is particularly relevant for strategy.
Related Cases
OrthoApnea S.L.vsVivisol B BV
This UPC appeal addressed a procedural request by Vivisol B BV seeking to suspend proceedings and extend deadlines related to an infringement action brought by OrthoApnea S.L. The Court of Appeal ultimately rejected the suspension request, ruling that parties must adhere to standard litigation procedures regardless of potential future appellate outcomes. This decision reinforces the principle that procedural steps in UPC cases must proceed without undue delay, even when substantive issues are under appeal.
Avago Technologies International Sales Pte. LimitedvsRealtek Semiconductor Corporation
This UPC decision addresses a procedural gap regarding the reimbursement of court fees when an application for interim measures is withdrawn. The Court ruled that despite the strict wording of the Rules of Procedure, the principle allowing fee recovery upon withdrawal could be analogously applied to interim measure applications. This provides clarity and predictability for practitioners dealing with early-stage litigation in the UPC.
Promosome LLCvsBioNTech SE, BioNTech Manufacturing GmbH, BioNTech Manufacturing Marburg GmbH, BioNTech Innovative Manufacturing Services GmbH, BioNTech Europe GmbH, Pfizer Manufacturing Belgium NV, Pfizer SAS, Pfizer AB, Pfizer, Inc.
In this procedural order, the UPC granted Promosome LLC's request to classify specific exhibits (VB 4a and VB 4b), which contain confidential license agreement terms between the parties, as confidential. The ruling establishes strict limitations on who can access this sensitive information, restricting it primarily to authorized legal representatives and their support staff. This decision reinforces the UPC's commitment to protecting trade secrets within ongoing infringement actions.
AIM Sport Development AGvsSupponor Oy, Supponor Limited, Supponor SASU, Supponor Italia SRL, Supponor España SL
This UPC Court of Appeal decision clarifies a critical point regarding the transitional regime: whether prior national court proceedings can block an effective withdrawal of an opt-out. The Court held that Art. 83(4) UPCA only restricts actions brought during the transitional period, meaning pre-transitional litigation does not invalidate a subsequent opt-out withdrawal. This ruling provides significant clarity and relief for patent holders seeking to utilize the UPC system after initially opting out.
Abbott Diabetes Care Inc.vsDexcom Inc.
In a procedural order issued on January 29, 2025, the UPC Court of First Instance allowed all parties in the dispute between Abbott Diabetes Care Inc. and Dexcom Inc. to withdraw their respective claims for infringement and revocation concerning patent EP4070727. While the substantive dispute was dropped, the court addressed procedural matters, setting the value of the cases at EUR 4 million and ordering a partial reimbursement of court fees.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.